NO985299L - Preparat av prostaglandin I-derivat med langsom frigj÷ring - Google Patents

Preparat av prostaglandin I-derivat med langsom frigj÷ring

Info

Publication number
NO985299L
NO985299L NO985299A NO985299A NO985299L NO 985299 L NO985299 L NO 985299L NO 985299 A NO985299 A NO 985299A NO 985299 A NO985299 A NO 985299A NO 985299 L NO985299 L NO 985299L
Authority
NO
Norway
Prior art keywords
prostaglandin
derivatives
slow release
release
release prostaglandin
Prior art date
Application number
NO985299A
Other languages
English (en)
Norwegian (no)
Other versions
NO985299D0 (no
Inventor
Michio Hara
Yasuhide Horiuchi
Fuminori Tamura
Keishi Yamasaki
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of NO985299D0 publication Critical patent/NO985299D0/no
Publication of NO985299L publication Critical patent/NO985299L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO985299A 1997-03-14 1998-11-13 Preparat av prostaglandin I-derivat med langsom frigj÷ring NO985299L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6150197 1997-03-14
PCT/JP1998/001057 WO1998041210A1 (en) 1997-03-14 1998-03-13 Sustained-release prostaglandin i derivative preparation

Publications (2)

Publication Number Publication Date
NO985299D0 NO985299D0 (no) 1998-11-13
NO985299L true NO985299L (no) 1999-01-14

Family

ID=13172913

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985299A NO985299L (no) 1997-03-14 1998-11-13 Preparat av prostaglandin I-derivat med langsom frigj÷ring

Country Status (13)

Country Link
US (1) US6656502B1 (de)
EP (1) EP0947196B1 (de)
JP (1) JP3744941B2 (de)
CN (1) CN100502877C (de)
AT (1) ATE433753T1 (de)
AU (1) AU6310898A (de)
CA (1) CA2255052C (de)
DE (1) DE69840908D1 (de)
DK (1) DK0947196T3 (de)
ES (1) ES2328191T3 (de)
NO (1) NO985299L (de)
PT (1) PT947196E (de)
WO (1) WO1998041210A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092760A1 (en) * 2001-03-12 2003-05-15 Toray Industries, Inc. Therapeutic agent for renal failure
WO2004034959A2 (en) * 2002-09-18 2004-04-29 Elan Corporation, Plc Multiparticulate modified release composition comprising beraprost
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
ATE341312T1 (de) * 2003-05-20 2006-10-15 Ethypharm Sa Orale pharmazeutische zusammensetzung mit verzögerter freisetzung
ES2670872T3 (es) 2003-05-22 2018-06-01 United Therapeutics Corporation Polimorfo de una sal de dietanolamina de treprostinil
US7063862B2 (en) 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
US9205047B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
US20120184622A1 (en) * 2009-08-07 2012-07-19 Scipharm Sarl Composition for the treatment of cystic fibrosis
CN102740855B (zh) 2010-02-12 2013-11-27 大正制药株式会社 缓释制剂
CN106822013B (zh) * 2015-11-30 2020-05-12 北京泰德制药股份有限公司 前列环素类似物缓释制剂
CN107496348A (zh) * 2017-08-28 2017-12-22 天津昂赛细胞基因工程有限公司 一种用于组织损伤修复的水凝胶及制备方法
TW201922230A (zh) 2017-11-16 2019-06-16 日商日本新藥股份有限公司 控釋製劑
US12427145B2 (en) 2019-02-03 2025-09-30 Innovate Therapeutics Llc Controlled release pharmaceutical composition of Selexipag or it's active metabolite
EP4082549A4 (de) 2019-12-23 2023-09-06 Toray Industries, Inc. Arzneimittel zur verhinderung von dialyseänderung oder nierentod
JP7728347B2 (ja) * 2020-12-22 2025-08-22 ラジオメーター・メディカル・アー・ペー・エス 抗血小板剤および水溶性マトリックス材料を含有する血液サンプラー
MX2023013545A (es) 2021-06-16 2023-11-29 Toray Industries Metodo terapeutico para gato con enfermedad renal cronica.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
JPS58124778A (ja) * 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
DK152744C (da) * 1982-08-13 1988-10-31 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat
JPH0759521B2 (ja) * 1985-09-30 1995-06-28 藤沢薬品工業株式会社 ゲル層形成型徐放性製剤
GB8616669D0 (en) * 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
JPH02218621A (ja) * 1989-02-20 1990-08-31 Nippon Chemiphar Co Ltd 徐放性製剤
JPH02225416A (ja) * 1989-02-28 1990-09-07 Toray Ind Inc ５，６，７―トリノル―４，８―インタ―ｍ―フェニレンＰＧＩ↓２誘導体の経口用製剤
JP3007387B2 (ja) * 1990-07-16 2000-02-07 エーザイ株式会社 徐放性製剤用基剤粉末
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form

Also Published As

Publication number Publication date
EP0947196A1 (de) 1999-10-06
ES2328191T3 (es) 2009-11-10
WO1998041210A1 (en) 1998-09-24
EP0947196B1 (de) 2009-06-17
CA2255052A1 (en) 1998-09-24
CA2255052C (en) 2009-09-15
NO985299D0 (no) 1998-11-13
CN1219132A (zh) 1999-06-09
JP3744941B2 (ja) 2006-02-15
US6656502B1 (en) 2003-12-02
PT947196E (pt) 2009-09-24
AU6310898A (en) 1998-10-12
EP0947196A4 (de) 2005-01-12
ATE433753T1 (de) 2009-07-15
CN100502877C (zh) 2009-06-24
DE69840908D1 (de) 2009-07-30
DK0947196T3 (da) 2009-10-12

Similar Documents

Publication Publication Date Title
NO985299D0 (no) Preparat av prostaglandin I-derivat med langsom frigj°ring
NO890075D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazoler.
PT1452524E (pt) Derivado de 2-oxo-1-pirrolidina e suas utilizações farmacêuticas
NO20016107D0 (no) Mesalazin-kontrollert frigivelse orale farmasöytiske sammensetninger
DE69528005D1 (de) Prolineamid-Derivate
DE69418243D1 (de) N-Heteroaryl-N'-Phenylharnstoffderivate, ihre Herstellung und Verwendung
EP1077065A4 (de) Präparationen zur kontrollierten freisetzung
NO951055D0 (no) Galeniske former for forlenget frigivelse av alfuzosinhydroklorid
IL96882A0 (en) Uracil derivatives and pesticides containing the same as active ingredient
NO20013060D0 (no) Kontrollert frigjörende farmasöytisk preparat med tilidinmesylat som virkestoff
WO2001027110A3 (de) Am sechsring substituierte, bicyclische imidazo-3-yl-aminderivate
DK0966277T3 (da) Anvendelse af R-NSAID'er til forebyggelse af Alzheimer's sygdom
EP1666041A3 (de) Xanthinderivate zur Behandlung neurodegenerativer Störungen
PT806202E (pt) Composicao farmaceutica a base de matrizes lipofilas estabilizadas para a libertacao controlada de principios activos
BR0012791A (pt) Derivados de oxazino-carbazóis
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
AU1042888A (en) Pain-killer
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
WO1998038985A3 (en) Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases
DE60026559D1 (de) Arzneimittel gegen essstörungen
AP9200405A0 (en) Pharmaceutical formulations comprised of micronised halofantrine.
WO2002036554A3 (en) Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis
NO890328D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 4-amino-2,3-disubstituert-6,7-dihydro-5h-1-pyrindinderivater.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application